AHL
IPSC icon

Abel Hall LLC’s Century Therapeutics IPSC Stock Holding History

Abel Hall LLC’s Portfolio IPSC Stock Details IPSC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-17,582
Closed -$9.82K – 345
2025
Q2 		$9.82K Buy
+17,582
New +$9.43K ﹤0.01% 283
2024
Q2 		– Sell
-10,071
Closed -$42.1K – 153
2024
Q1 		$42.1K Hold
10,071
– – 0.03% 137
2023
Q4 		$33.4K Buy
+10,071
New +$18.3K 0.03% 119

Other funds holding IPSC

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
SP
Syncona Portfolio St Peter Port, Guernsey $25.7M AUM 13.32% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Abel Hall LLC's IPSC Position: Q3 2025 in Review

Abel Hall LLC sold out of Century Therapeutics (IPSC) in Q3 2025, closing a stake of 17,582 shares — an estimated $9.82K sold.

Abel Hall LLC first reported a position in IPSC in Q4 2023 and held it in 3 quarters. The position peaked at $42.1K in Q1 2024. 57 funds tracked by Wall St. Rank hold IPSC as of Q3 2025.

  • Abel Hall LLC reported no remaining Century Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Abel Hall LLC sold 17,582 Century Therapeutics shares in Q3 2025, an estimated $9.82K.
  • Abel Hall LLC first reported a position in Century Therapeutics in Q4 2023 and held it in 3 quarters.
  • Abel Hall LLC's Century Therapeutics position peaked at $42.1K in Q1 2024.
  • 57 funds tracked by Wall St. Rank held Century Therapeutics as of Q3 2025.

Based on Abel Hall LLC's 13F filing for Q3 2025, filed 17 Nov 2025.